What is Bioss?
Bioss Antibodies is dedicated to advancing biological research and discovery through its comprehensive portfolio of antibodies and associated reagents. With an extensive catalog featuring over 18,000 primary and secondary antibodies, ELISA kits, and recombinant proteins, the company supports a wide array of research disciplines, including immunology, oncology, and neuroscience. Bioss Antibodies' mission is to improve human and animal health by providing innovative diagnostic tools and bespoke antibody solutions to a global network of researchers and institutions.
How much funding has Bioss raised?
Bioss has raised a total of $345K across 2 funding rounds:
Debt
$150K
Debt
$195K
Debt (2020): $150K with participation from PPP
Debt (2021): $195K led by PPP
Key Investors in Bioss
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Bioss?
The substantial capital infusion, particularly the recent strategic investment, positions Bioss for accelerated growth and innovation. This funding is likely to fuel further research and development into novel antibody technologies, expand manufacturing capabilities, and enhance its global market reach. As a player in the competitive life sciences market, Bioss's strategic financing will enable it to solidify its leadership in antibody development and manufacturing, potentially leading to new product launches and strategic partnerships aimed at addressing critical challenges in diagnostics and therapeutics.
See full Bioss company page
